Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis

References

• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• World Health Organization. [cited 2023 Mar 17]. Available from: https://covid19.who.int/
   Google Scholar
• Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412. doi: 10.1016/j.jmii.2020.02.012
   PubMedGoogle Scholar
• Kowsar R, Rahimi AM, Sroka M, et al. Risk of mortality in COVID-19 patients: a meta- and network analysis. Sci Rep. 2023;13(1):2138. doi: 10.1038/s41598-023-29364-8
   PubMedGoogle Scholar
• Xourgia E, Katsaros DE, Xixi NA, et al. Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries. Expert Rev Respir Med. 2022;16(10):1101–1108. doi: 10.1080/17476348.2022.2145950
   PubMed Web of Science ®Google Scholar
• Lai CC, Lee PI, Hsueh PR. How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022. J Microbiol Immunol Infect. 2023;56(3):433–441. doi: 10.1016/j.jmii.2023.04.001
   PubMedGoogle Scholar
• Lai CC, Hsu CK, Yen MY, et al. Long COVID: an inevitable sequela of SARS-CoV-2 infection. J Microbiol Immunol Infect. 2023;56(1):1–9. doi: 10.1016/j.jmii.2022.10.003
   PubMedGoogle Scholar
• Zhang YJ, Sun XF, Xie B, et al. Exploration of severe covid-19 associated risk factor in China: meta-analysis of current evidence. Int J Clin Pract. 2021;75(12):e14900. doi: 10.1111/ijcp.14900
   PubMed Web of Science ®Google Scholar
• Vardavas CI, Mathioudakis AG, Nikitara K, et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022;31(166):31. doi: 10.1183/16000617.0098-2022
   Web of Science ®Google Scholar
• Wu Y, Li H, Zhang Z, et al. Risk factors for mortality of coronavirus disease 2019 (COVID-19) patients during the early outbreak of COVID-19: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(5):5069–5083. doi: 10.21037/apm-20-2557
   PubMed Web of Science ®Google Scholar
• Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):612–620. doi: 10.1007/s12072-020-10078-2
   PubMed Web of Science ®Google Scholar
• Huang SM, Wu CH, Yen TY, et al. Clinical characteristics and factors associated with severe COVID-19 in hospitalized children during the SARS-CoV-2 Omicron pandemic in Taiwan. J Microbiol Immunol Infect. 2023;56(5):961–969. doi: 10.1016/j.jmii.2023.06.001
   PubMedGoogle Scholar
• Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. Liver Int. 2020;40(10):2515–2521. doi: 10.1111/liv.14583
   PubMed Web of Science ®Google Scholar
• Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury spectrum study). Hepatol Int. 2020;14(5):690–700. doi: 10.1007/s12072-020-10072-8
   PubMed Web of Science ®Google Scholar
• Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159(2):768–71.e3. doi: 10.1053/j.gastro.2020.04.064
   PubMed Web of Science ®Google Scholar
• Wong RJ, Zhang Y, Thamer M. Chronic liver disease and cirrhosis are associated with worse outcomes following SARS-CoV-2 infection. J Clin Exp Hepatol. 2023;13(4):592–600. doi: 10.1016/j.jceh.2023.01.014
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Wang J, Tadrous M, et al. Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19. CMAJ. 2023;195(6):E220–e6. doi: 10.1503/cmaj.221608
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23(6):696–705. doi: 10.1016/S1473-3099(23)00011-7
   PubMed Web of Science ®Google Scholar
• Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health System: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. doi: 10.7326/M22-2141
   PubMed Web of Science ®Google Scholar
• Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54(5):767–775. doi: 10.1016/j.jmii.2021.05.011
   PubMedGoogle Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022 Sep 5;ciac724. Online ahead of print.
   PubMedGoogle Scholar
• Hayward KL, Johnson AL, McKillen BJ, et al. ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. BMJ Open Gastroenterol. 2020;7(1):e000485. doi: 10.1136/bmjgast-2020-000485
   PubMed Web of Science ®Google Scholar
• Krishnan A, Patel RA, Hadi YB, et al. Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: a population-based matched cohort study. World J Hepatol. 2023;15(1):68–78. doi: 10.4254/wjh.v15.i1.68
   PubMed Web of Science ®Google Scholar
• Thandassery RB, Sharma S, Syed M, et al. A global multicenter propensity-matched analysis of mortality risk and palliative care referral due to cirrhosis in hospitalized patients with COVID-19. J Clini Transl Res. 2022;8(5):414.
   Google Scholar
• Liu TH, Wu JY, Huang PY, et al. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.014
   Web of Science ®Google Scholar
• Tsai YW, Tsai CF, Wu JY, et al. The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: a retrospective cohort study from the TriNetX network. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2023.01.006
   Web of Science ®Google Scholar
• Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638. doi: 10.1001/jama.2015.13480
   PubMed Web of Science ®Google Scholar
• Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585–591. doi: 10.1007/s40265-022-01692-5
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. [cited 2023 Feb 28]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Mbaeyi S, Oliver SE, Collins JP, et al. The advisory committee on immunization practices’ Interim recommendations for additional primary and booster doses of COVID-19 vaccines — United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1545–1552. doi: 10.15585/mmwr.mm7044e2
   PubMed Web of Science ®Google Scholar
• Neumann NR, Chai PR, Wood DM, et al. Medical toxicology and COVID-19: our role in a pandemic. J Med Toxicol. 2020;16(3):245–247. doi: 10.1007/s13181-020-00778-4
   PubMed Web of Science ®Google Scholar
• Ross SB, Bortolussi-Courval É, Hanula R, et al. Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications. JAMA Netw Open. 2022;5:e2220184. doi: 10.1001/jamanetworkopen.2022.20184
   PubMed Web of Science ®Google Scholar
• Azanza JR, Mensa J, González Del Castillo J, et al. Interactions listed in the paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences. Rev Esp Quimioter. 2022;35(4):357–361. doi: 10.37201/req/054.2022
   PubMed Web of Science ®Google Scholar